Lyell Immunopharma, Inc. Ratios

Ratios Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
EBT Margin -14,302.59%-2,655.98%-2,005.74%-212.56%-171,965.38%-548,667.21%
EBIT Margin -15,538.66%-2,732.56%-2,016.68%-220.89%-190,006.15%-588,122.95%
EBITDA Margin -19,622.98%-2,638.86%-2,367.12%-223.30%-174,713.08%-561,654.10%
Operating Margin -15,538.66%-2,732.56%-2,016.68%-220.89%-190,006.15%-588,122.95%
Net Margin -19,866.21%-2,682.49%-2,349.47%-216.24%-171,965.38%-548,667.21%
FCF Margin 3,565.75%-2,737.94%-1,800.50%-228.89%-127,984.62%-266,980.33%
Efficiency
Assets Average 1,017.84M1,032.48M843.79M620.44M
Equity Average -201.82M318.63M881.52M744.10M518.89M
Invested Capital -111.11M-292.53M929.79M833.25M654.95M382.82M
Asset Utilization Ratio 0.010.080.000.00
Leverage & Solvency
Equity Ratio -0.320.820.890.870.78
Valuation
Enterprise Value -96.67M-612.62M1,246.46M225.01M175.41M-191.83M
Market Capitalization 1,861.25M865.16M721.63M178.70M
Return Ratios
Return on Sales -143.03%-26.56%-20.06%-2.13%
Return on Capital Employed -0.22%-0.19%-0.31%-0.63%
Return on Assets -0.21%-0.17%-0.26%-0.54%
Return on Equity 1.02%-0.67%-0.20%-0.30%-0.65%